Steven L. Chang, MD, MS, Named Section Chief of Urologic Oncology

Dr. Chang will lead the newly formed Section of Urologic Oncology within the Division of Urology in the Department of Surgery at Brigham Health.

Dr. Steven Chang is an associate surgeon at Brigham and Women’s Hospital and Dana-Farber/Brigham and Women’s Cancer Center and is an assistant professor of surgery at Harvard Medical School.

Dr. Chang received his medical degree from Columbia University, College of Physicians and Surgeons, and completed a urology residency as well as a urologic oncology fellowship at Stanford University Medical Center. During his fellowship training, Dr. Chang earned a Master of Science in Health Services Research from the Department of Health Research and Policy at Stanford University Medical School. He is board certified in urology.

Dr. Chang cares for patients with urologic cancers, using minimally invasive surgical approaches with laparoscopy and robotics. He is particularly interested in the management of kidney cancer and has established collaborations with medical oncologists at Dana-Farber/Brigham and Women’s Cancer Center and interventional radiologists at Brigham and Women’s Hospital to treat patients with kidney tumors, ranging from incidentally detected small renal masses to metastatic renal cell carcinoma.

Dr. Chang’s research focuses on reducing the overall burden of urologic cancers on the health care system. His clinical specialties include: kidney cancer, prostate cancer, bladder cancer, adrenal cancer, testicular cancer and reconstructive kidney surgery.

Thomas G. Gleason, MD, Named Chief of Cardiac Surgery at Brigham Health

After an extensive national search, Thomas G. Gleason, MD, has been named chief of Cardiac Surgery and co-executive director of the Heart and Vascular Center at Brigham Health, effective May 1, 2020.

Thomas G. Gleason, MD

Dr. Gleason is currently the Ronald V. Pellegrini Endowed Professor of Cardiothoracic Surgery and chief of the Division of Cardiac Surgery at the University of Pittsburgh School of Medicine where he also serves as the co-director of the Heart and Vascular Institute and director of the Center for Thoracic Aortic Disease at the University of Pittsburgh Medical Center (UPMC). In these roles, he directs UPMC’s adult cardiac surgery programs for its many Pennsylvania-based hospitals that provide cardiac surgical services and co-directs the cardiovascular disease service line for UPMC.

A graduate of Middlebury College (BS) in Vermont and Rush Medical College (MD) in Chicago, Dr. Gleason completed his general surgical internship and residency at the University of Virginia where he also obtained a Master of Science in Immunology. He completed a cardiothoracic surgery residency and an advanced cardiac and thoracic aortic fellowship at the University of Pennsylvania. He has held faculty positions at the University of Pennsylvania and Northwestern University prior to joining UPMC.

Dr. Gleason has extensive clinical experience managing patients with valvular heart disease, thoracic aortic disease, hypertrophic obstructive cardiomyopathy, coronary artery disease and atrial fibrillation. His clinical research interests are primarily focused on the development and refinement of novel valve therapies, particularly aortic valve repair strategies, and in developing a systematic approach toward the management of aortic dissections. His longstanding basic science research interest has been devoted to the study of the aortopathy associated with congenital bicuspid aortic valves (BAV)—the most common phenotype seen among patients with ascending aortic aneurysmal disease. His multidisciplinary Thoracic Aortic Disease Research Laboratory aims to facilitate translational research of the vascular biology and biomechanics of thoracic aortic diseases. The laboratory maintains a robust thoracic aortic tissue bank that now houses over 1,000 distinct aortic smooth muscle cell lines and 150 aortic endothelial cell lines, many of which have been immortalized, all used as the framework for this translational human cell-based research.

Dr. Gleason is a member of the American Society for Clinical Investigation, the American Surgical Association and the American Association for Thoracic Surgery. He was a permanent member (2014-2019) of the Bioengineering, Technology, and Surgical Sciences (BTSS) Study Section for the Center for Scientific Review at the National Institutes of Health, and he currently serves on the editorial board of Circulation. He serves on the National Steering Committee for the STS/ACC TVT Registry and is co-chair of the Research and Publications Committee for the TVT. He is a fellow of the American Heart Association, the American College of Surgeons, the American College of Cardiology and the American College of Chest Physicians.

“Dr. Gleason will be bringing a wealth of clinical, academic and research leadership to his new Brigham roles,” Gerard Doherty, MD, chair of the Department of Surgery says. “I am confident that he will be highly effective in building on the strong foundation we have in place within our cardiac surgery programs and in partnering with John F. Keaney, Jr., MD, chief of Cardiovascular Medicine, to provide strategic oversight of the Heart and Vascular Center.”